Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PMD-MSCs for Peyronie's Disease
NCT02395029Phase 1Completed
- Start
- Aug 2013
- Primary completion
- Dec 2014
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of placental matrix-derived mesenchymal stem cells in Peyronie's disease. Primary endpoint: Peak Systolic Velocity without trimix at 12 months. Started Aug 2013; status: completed.
02
Drugs
placental matrix-derived mesenchymal stem cells
03
Conditions
Peyronie's disease
Beyond the preview
Go deeper on NCT02395029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02395029.